Palliative Inotropes in Advanced Heart Failure : Comparing Outcomes Between Milrinone and Dobutamine
Copyright © 2022. Published by Elsevier Inc..
BACKGROUND: We sought to describe and compare outcomes among advanced patients with heart failure (not candidates for orthotopic heart transplant/left ventricular assist device) on long-term milrinone or dobutamine, which are not well-studied in the contemporary era.
METHODS AND RESULTS: We included adults with refractory stage D heart failure who were not candidates for orthotopic heart transplant or left ventricular assist device and discharged on palliative dobutamine or milrinone. The primary outcome was 1-year survival. A 6-month predictor of survival analysis was conducted. A total of 248 patients (133 on milrinone, 115 on dobutamine) were included. There were no differences in baseline comorbidities between milrinone and dobutamine cohorts, except for the prevalence of chronic kidney disease, which was higher in the dobutamine group. On discharge, the proportion of patients on beta-blockers and mineralocorticoid antagonists was higher in milrinone group. Overall, the 1-year mortality rate was 70%. The dobutamine cohort had a significantly higher 1-year mortality rate (84% vs 58%, P <0.001). The type of inotrope did not predict survival at 6 months when adjusted for discharge medications and comorbidities. Beta-blockers and angiotensin-converting enzyme/angiotensin receptor blocker/angiotensin receptor neprilysin inhibitor continued at discharge predicted survival at 6 months.
CONCLUSIONS: The 1-year mortality from palliative inotropes remains high. Compared with dobutamine, use of milrinone was associated with improved survival owing to better optimization of guideline-directed medical therapy, primarily beta-blocker therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Journal of cardiac failure - 28(2022), 12 vom: 16. Dez., Seite 1683-1691 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sami, Farhad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3S12J47372 |
|---|
| Anmerkungen: |
Date Completed 19.12.2022 Date Revised 06.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cardfail.2022.08.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346393159 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346393159 | ||
| 003 | DE-627 | ||
| 005 | 20231226031332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cardfail.2022.08.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346393159 | ||
| 035 | |a (NLM)36122816 | ||
| 035 | |a (PII)S1071-9164(22)00711-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sami, Farhad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Palliative Inotropes in Advanced Heart Failure |b Comparing Outcomes Between Milrinone and Dobutamine |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.12.2022 | ||
| 500 | |a Date Revised 06.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier Inc. | ||
| 520 | |a BACKGROUND: We sought to describe and compare outcomes among advanced patients with heart failure (not candidates for orthotopic heart transplant/left ventricular assist device) on long-term milrinone or dobutamine, which are not well-studied in the contemporary era | ||
| 520 | |a METHODS AND RESULTS: We included adults with refractory stage D heart failure who were not candidates for orthotopic heart transplant or left ventricular assist device and discharged on palliative dobutamine or milrinone. The primary outcome was 1-year survival. A 6-month predictor of survival analysis was conducted. A total of 248 patients (133 on milrinone, 115 on dobutamine) were included. There were no differences in baseline comorbidities between milrinone and dobutamine cohorts, except for the prevalence of chronic kidney disease, which was higher in the dobutamine group. On discharge, the proportion of patients on beta-blockers and mineralocorticoid antagonists was higher in milrinone group. Overall, the 1-year mortality rate was 70%. The dobutamine cohort had a significantly higher 1-year mortality rate (84% vs 58%, P <0.001). The type of inotrope did not predict survival at 6 months when adjusted for discharge medications and comorbidities. Beta-blockers and angiotensin-converting enzyme/angiotensin receptor blocker/angiotensin receptor neprilysin inhibitor continued at discharge predicted survival at 6 months | ||
| 520 | |a CONCLUSIONS: The 1-year mortality from palliative inotropes remains high. Compared with dobutamine, use of milrinone was associated with improved survival owing to better optimization of guideline-directed medical therapy, primarily beta-blocker therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Milrinone |2 NLM | |
| 650 | 7 | |a JU9YAX04C7 |2 NLM | |
| 650 | 7 | |a Dobutamine |2 NLM | |
| 650 | 7 | |a 3S12J47372 |2 NLM | |
| 650 | 7 | |a Cardiotonic Agents |2 NLM | |
| 650 | 7 | |a Adrenergic beta-Antagonists |2 NLM | |
| 700 | 1 | |a Acharya, Prakash |e verfasserin |4 aut | |
| 700 | 1 | |a Noonan, Grace |e verfasserin |4 aut | |
| 700 | 1 | |a Maurides, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Masry, Anas Abudan |e verfasserin |4 aut | |
| 700 | 1 | |a Bajwa, Suhaib |e verfasserin |4 aut | |
| 700 | 1 | |a Parimi, Nikhil |e verfasserin |4 aut | |
| 700 | 1 | |a Boda, Ilham |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Goyal, Amandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Mastoris, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Dalia, Tarun |e verfasserin |4 aut | |
| 700 | 1 | |a Sauer, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Bakel, Adrian VAN |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Zubair |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cardiac failure |d 1995 |g 28(2022), 12 vom: 16. Dez., Seite 1683-1691 |w (DE-627)NLM087692775 |x 1532-8414 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:12 |g day:16 |g month:12 |g pages:1683-1691 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cardfail.2022.08.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 12 |b 16 |c 12 |h 1683-1691 | ||